Drug Profile


Alternative Names: LAS-31025

Latest Information Update: 24 Aug 2009

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Almirall-Prodesfarma
  • Developer Almirall S.A.
  • Class Antiasthmatics; Small molecules; Xanthines
  • Mechanism of Action Type 4 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Asthma; Bronchitis; Chronic obstructive pulmonary disease

Most Recent Events

  • 24 Jun 2005 Phase-II clinical trials in Chronic obstructive pulmonary disease in Europe (PO)
  • 05 Apr 2004 No development reported - Phase-I for Asthma in Spain (Inhalation)
  • 05 Apr 2004 No development reported - Phase-III for Asthma in Spain (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top